Testing immune cell therapy after chemotherapy for blood cancer

Plain-English translation of NCT07072494 on ClinicalTrials.gov ↗ · Source last updated July 2025 · Translation generated July 2026 · How we translate trials

Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.

What is this trial?

This trial is testing CD19 CAR-T cell therapy as a follow-up treatment for teenagers and adults with acute B-cell leukemia who have already gone into remission with chemotherapy but cannot receive a stem cell transplant. The study will give participants this engineered immune cell medication after chemotherapy to see if it helps keep the cancer away longer and improves survival. Researchers will carefully watch for both how well it works and any side effects.

Stem cell transplants are the standard follow-up treatment for many leukemia patients, but not everyone can have one due to age, health problems, or lack of a suitable donor. This trial is exploring whether this engineered immune cell treatment could be a helpful alternative for patients who don't qualify for transplant.

Do you qualify?

You likely qualify if…

you have been diagnosed with acute B-cell leukemia (including Burkitt leukemia) and have achieved complete remission after chemotherapy
you are between 14 and 80 years old
you are not eligible for stem cell transplant, don't have a suitable donor, or have chosen not to have one
your cancer cells are CD19-positive (confirmed by blood or bone marrow test)
your heart, lungs, liver, and kidneys are working well enough for this treatment
you are expected to live for at least three more months

You likely don't qualify if…

you have been treated with CAR-T cell therapy before
you have a genetic bone marrow failure syndrome (like Fanconi anemia)
you have untreated viral infections including hepatitis B, hepatitis C, HIV, or active EBV or CMV
you have had another cancer in the past five years

What participation looks like

You will first receive standard chemotherapy to prepare your body. Then your own immune cells will be collected from your blood, sent to a lab to be engineered, and infused back into you through an IV. After the infusion, you will have frequent hospital visits and blood tests over several months to monitor how you respond and watch for any side effects. The study will follow you for up to three years to track how long the treatment helps keep your cancer in remission.

AI-generated summary from trial data · Jul 15, 2026 · Not medical advice

Trial locations(2 sites)

China

Zhujiang Hospital, Guangzhou, Guangdong